Edison Investment Research - Pharmaceuticals & healthcare - MetrioPharm: MetrioPharm is a private European clinical drug development company. Its first drug, the reactive oxygen species (ROS) scavenger MP1032, has anti-inflammatory activity and has completed a Phase II for psoriasis with potential in other diseases. Our risk-adjusted valuation of MetrioPharm across all indications is CHF253m based on MP1032.
ISIN: CH0107076744
Original Article: MetrioPharm (NA1) - Creating an ideal target product profile